Hospital
Baylor University Medical Center
Baylor University Medical Center was paid $14.65M by Medicaid between Jan 2019 and Dec 2024, across 178 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoBAYLOR UNIVERSITY MEDICAL CENTER
DALLAS, TX 75246
DALLAS, TX 75246
33aNPI1447250253assigned 07/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.65M
24GClaims336,689
24DCodes billed178
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#9 of 109
Median peer was paid$1.15M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,238 | $22K | |
| 2020 | 25,644 | $650K | |
| 2021 | 83,549 | $3.42M | |
| 2022 | 83,736 | $5.16M | |
| 2023 | 87,721 | $3.55M | |
| 2024incomplete | 54,801 | $1.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 17,558 | 15,462 | $5.58M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 5,674 | 4,948 | $2.05M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.6% | 13,304 | 10,732 | $815K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.0% | 2,900 | 2,610 | $739K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 4.8% | 1,758 | 1,496 | $699K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 4,252 | 3,750 | $446K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.5% | 10,692 | 9,321 | $370K |
| 80053 | Comprehensive metabolic panel | 2.4% | 29,376 | 23,414 | $348K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 11,652 | 9,887 | $303K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 29,625 | 23,551 | $235K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 1,933 | 1,722 | $203K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 3,938 | 3,231 | $195K |
166 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 2,563 | $182K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 1,379 | $178K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 4,994 | $156K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 567 | $110K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,316 | $109K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 612 | $103K |
| 93975 | <1% | 571 | $101K | |
| 83880 | <1% | 3,788 | $101K | |
| 84484 | <1% | 7,701 | $97K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,007 | $95K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 340 | $88K |
| 76801 | <1% | 934 | $88K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,193 | $66K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,794 | $64K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 784 | $64K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,629 | $60K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,630 | $60K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,073 | $35K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 733 | $32K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,766 | $32K |
| 84703 | <1% | 4,121 | $31K | |
| 83690 | <1% | 5,404 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,511 | $27K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,881 | $25K |
| 82803 | <1% | 1,072 | $24K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 30 | $24K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,763 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 153 | $23K |
| 93971 | <1% | 232 | $22K | |
| 81001 | <1% | 7,440 | $21K | |
| 73030 | <1% | 625 | $21K | |
| 83605 | <1% | 2,011 | $21K | |
| 70486 | <1% | 187 | $19K | |
| 86850 | <1% | 962 | $18K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 191 | $18K |
| 90715 | <1% | 603 | $18K | |
| 85027 | <1% | 3,336 | $16K | |
| 0001A | <1% | 1,300 | $15K | |
| 85730 | <1% | 3,363 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,266 | $15K |
| 0002A | <1% | 1,361 | $15K | |
| 85610 | <1% | 4,641 | $14K | |
| 83735 | <1% | 3,755 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 137 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 620 | $13K |
| 81025 | <1% | 1,562 | $13K | |
| 73630 | <1% | 284 | $13K | |
| 87040 | <1% | 926 | $13K | |
| 84702 | <1% | 1,640 | $12K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 656 | $12K |
| 73502 | <1% | 261 | $11K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 857 | $10K |
| 82330 | <1% | 829 | $10K | |
| 73560 | <1% | 287 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 778 | $9K |
| 72131 | <1% | 72 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,451 | $9K |
| 73562 | <1% | 195 | $9K | |
| 70498 | <1% | 43 | $9K | |
| 87210 | <1% | 1,470 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 69 | $8K |
| 73610 | <1% | 177 | $8K | |
| 93970 | <1% | 30 | $8K | |
| 84132 | <1% | 1,709 | $7K | |
| 73130 | <1% | 199 | $7K | |
| 85007 | <1% | 2,072 | $7K | |
| 81003 | <1% | 3,423 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 50 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 254 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,172 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,931 | $6K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 820 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 626 | $5K |
| 85379 | <1% | 676 | $5K | |
| 86900 | <1% | 1,908 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,039 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 835 | $5K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 18 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,362 | $4K |
| 86901 | <1% | 1,739 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,202 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 60 | $4K |
| 84295 | <1% | 883 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 114 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,647 | $3K |
| 84100 | <1% | 2,124 | $3K | |
| 96376 | <1% | 655 | $3K | |
| 82947 | <1% | 878 | $3K | |
| 73590 | <1% | 87 | $3K | |
| 85014 | <1% | 1,178 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,349 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,365 | $2K |
| 87186 | <1% | 322 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 47 | $2K |
| 82550 | <1% | 445 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 325 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 148 | $2K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 15 | $2K |
| 87077 | <1% | 179 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $2K |
| 84450 | <1% | 355 | $2K | |
| 80061 | Lipid panel | <1% | 193 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 107 | $2K |
| 86833 | <1% | 32 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,135 | $1K |
| 84460 | <1% | 195 | $1K | |
| 86832 | <1% | 30 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 112 | $793.56 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 95 | $676.38 |
| 72170 | <1% | 14 | $644.04 | |
| 93308 | <1% | 16 | $520.31 | |
| 36430 | <1% | 72 | $496.35 | |
| 86140 | <1% | 175 | $495.22 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 156 | $458.31 |
| 94618 | <1% | 14 | $423.84 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,531 | $422.13 |
| 73110 | <1% | 13 | $414.00 | |
| 0003A | <1% | 159 | $412.56 | |
| 82565 | <1% | 151 | $409.53 | |
| 86923 | <1% | 17 | $406.17 | |
| 82962 | <1% | 5,465 | $405.82 | |
| 80069 | <1% | 111 | $315.59 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 882 | $308.01 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 65 | $301.82 |
| 73060 | <1% | 15 | $288.97 | |
| 82728 | <1% | 26 | $280.54 | |
| 94760 | <1% | 20 | $268.14 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 250 | $254.41 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 18 | $250.28 |
| 84145 | <1% | 15 | $227.70 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 263 | $222.62 |
| 83550 | <1% | 27 | $202.57 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 28 | $201.30 |
| 87799 | <1% | 158 | $192.25 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 184 | $178.18 |
| 83540 | <1% | 27 | $149.84 | |
| 85651 | <1% | 56 | $135.50 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 14 | $111.99 |
| 80197 | <1% | 1,693 | $111.95 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 190 | $98.59 |
| 90686 | <1% | 29 | $86.22 | |
| 87205 | <1% | 25 | $54.06 | |
| 82310 | <1% | 22 | $30.31 | |
| 82247 | <1% | 20 | $29.54 | |
| 82040 | <1% | 20 | $29.12 | |
| 82374 | <1% | 23 | $28.70 | |
| 82435 | <1% | 22 | $27.02 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 16 | $23.66 |
| 84520 | <1% | 22 | $23.24 | |
| 84075 | <1% | 16 | $21.75 | |
| 84155 | <1% | 21 | $21.56 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 24 | $18.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,058 | $0.53 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 895 | $0.24 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 6,215 | $0.01 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 49 | $0.00 |
| 36592 | 0% | 178 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 25 | $0.00 |
| 0004A | 0% | 27 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 12 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 156 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 90 | $0.00 |
| 94010 | 0% | 28 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 116 | $0.00 |
| 36416 | 0% | 32 | $0.00 | |
| 88342 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARMSTRONG, KYLE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Baylor University Medical Center | Dallas, TX | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.